Is deafness mutation screening required in cystic fibrosis patients?

Abstract excerpt

Aminoglycosides are widely used in cystic fibrosis management. The m.1555A>G mutation predisposes to aminoglycoside ototoxicity. It may cause later onset hearing loss in the absence of aminoglycosides use and gradual hearing loss may be an inevitable consequence of the mutation. Given that aminoglycoside therapy forms the backbone of IV protocols in CF, this article recommends screening for this mutation to allow...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adolescent
• Share to Aminoglycosides
• Share to Consanguinity